2021

Fabrazyme®

Educational materials on home infusion therapy with Fabrazyme® (agalsidase beta) for patients with Fabry disease and healthcare professionals: organization of treatment, preparation, reconstitution, dilution, and administration of the medicinal product, safety assessment, and keeping an infusion log. generated automatically

Gilenya* (fingolimod)

Risk management information materials on the use of fingolimod: a pregnancy reminder card for patients, a checklist for physicians, and guidelines for patients, parents and caregivers. Intended for healthcare professionals and patients. compiled automatically

LEFLUTAB Information letter for patients

Patient information letter on the medicinal product Leflutab: warnings about risks to the unborn child, contraception rules during treatment, and the "washout" procedure for women and men. generated automatically

Risk of blood clot formation when taking combined hormonal contraceptives, for risk minimization of the medicinal product Midiana

Information card for women on the risk of blood clot formation while taking combined hormonal contraceptives. Contains a list of increased risk factors, symptoms for which medical help should be sought immediately, and recommendations on informing the doctor. compiled automatically

Soliqua

Training guide for patients and their caregivers on the use of prefilled pens containing the combination of insulin glargine and lixisenatide. Contains recommendations on choosing the pen type, dosing and injection rules. compiled automatically

Regarding risk minimization when using the medicinal product Humira®

Information card for an adult patient using Humira (adalimumab), with fields for entering patient, physician and injection data, as well as a list of symptoms of possible adverse reactions and information on tuberculosis screening. compiled automatically

Tablets with a changed composition of excipients Euthyrox® (levothyroxine): monitoring of patients switching between tablets

Information letter for patients on the switch to levothyroxine tablets with a changed composition of excipients (lactose replaced with mannitol). Explains the indications, the absence of changes in safety and efficacy, the symptoms of thyroid imbalance and the need to monitor TSH. compiled automatically

FAVIPIRAVIR-MIKROKHIM

Information material for patients on the use of an antiviral medicinal product for the treatment of complicated forms of influenza: dosage, administration rules, precautions regarding pregnancy, breastfeeding, and contraception, as well as the procedure for reporting adverse reactions. generated automatically

MIFENAX®

Patient guide on the use of mycophenolate mofetil: contains information on the risks of spontaneous abortions and congenital malformations and measures to minimize them. Intended for patients who take or plan to take this medicine. compiled automatically

TECENTRIQ®